Drug Interactions between Duavee and eltrombopag

Consumer information for this interaction is not currently available.

MONITOR CLOSELY: Venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE) have occurred during treatment with eltrombopag. Concurrent use of other agents such as combined hormonal contraceptives, hormone replacement therapy (HRT), or estrogen receptor modulators may potentiate this risk. Eltrombopag is a thrombopoietin (TPO) receptor agonist that initiates signaling cascades leading to proliferation and differentiation of megakaryocytes, which increases platelet production. Thromboembolic events have been observed in Immune Thrombocytopenia Purpura (ITP) patients receiving eltrombopag even with low or normal platelet counts. In controlled clinical studies of thrombocytopenic patients with hepatitis C receiving interferon-based therapy (n=1,439), thromboembolic events occurred in 4% of patients receiving eltrombopag versus 1% receiving placebo. Additionally, a case report described the development of DVT and PE in a patient taking eltrombopag and hormonal contraceptives, although the event occurred 10 days after eltrombopag discontinuation. Hormonal contraceptives and HRT are listed among risk factors for thromboembolism in patients receiving eltrombopag. This risk may be further increased in individuals with inherited or acquired coagulation disorders, advanced age, prolonged periods of immobilization, malignancies, surgery, trauma, obesity, or smoking.

MANAGEMENT: Caution and close clinical monitoring are advised when eltrombopag is coadministered with combined hormonal contraceptives, HRT, and/or estrogen receptor modulators. Platelet counts should be closely monitored throughout treatment with consideration given to a dose reduction or discontinuation of eltrombopag if the platelet count exceeds the target levels. Patients and their caregivers should also be advised to seek medical attention if they experience signs and symptoms of a thromboembolic event, such as shortness of breath, chest pain, hemoptysis, or arm or leg swelling or pain.

Consumer information for this interaction is not currently available.

MONITOR CLOSELY: Venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE) have occurred during treatment with eltrombopag. Concurrent use of other agents such as combined hormonal contraceptives, hormone replacement therapy (HRT), or estrogen receptor modulators may potentiate this risk. Eltrombopag is a thrombopoietin (TPO) receptor agonist that initiates signaling cascades leading to proliferation and differentiation of megakaryocytes, which increases platelet production. Thromboembolic events have been observed in Immune Thrombocytopenia Purpura (ITP) patients receiving eltrombopag even with low or normal platelet counts. In controlled clinical studies of thrombocytopenic patients with hepatitis C receiving interferon-based therapy (n=1,439), thromboembolic events occurred in 4% of patients receiving eltrombopag versus 1% receiving placebo. Additionally, a case report described the development of DVT and PE in a patient taking eltrombopag and hormonal contraceptives, although the event occurred 10 days after eltrombopag discontinuation. Hormonal contraceptives and HRT are listed among risk factors for thromboembolism in patients receiving eltrombopag. This risk may be further increased in individuals with inherited or acquired coagulation disorders, advanced age, prolonged periods of immobilization, malignancies, surgery, trauma, obesity, or smoking.

MANAGEMENT: Caution and close clinical monitoring are advised when eltrombopag is coadministered with combined hormonal contraceptives, HRT, and/or estrogen receptor modulators. Platelet counts should be closely monitored throughout treatment with consideration given to a dose reduction or discontinuation of eltrombopag if the platelet count exceeds the target levels. Patients and their caregivers should also be advised to seek medical attention if they experience signs and symptoms of a thromboembolic event, such as shortness of breath, chest pain, hemoptysis, or arm or leg swelling or pain.